Answers are grounded in this paper and cite their sources.
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder characterized by sustained peripheral blood (PB) monocytosis, bone marrow (BM) dysplasia, and an inherent risk for transformation to acute myeloid leukemia (AML); ~20–30% over 3–5 years 1 , 2 . Patients with CMML have ~10–15 gene mutations in coding DNA regions, with common mutations involving TET2 (~60%), ASXL1 (~40%), SRSF2 (~40%), and the oncogenic RAS pathway (~30%) 3 . Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic malignancy of dendritic cell origin that is known to infiltrate the blood, BM, skin, and lymph nodes; a diagnosis of which is based on a blast immunophenotype characterized by the expression of CD4, CD43, CD56, CD123, BDCA-2/CD303, TCL1, and CTLA 1 . Cytogenetic studies, array-based comparative genomic hybridization, and gene expression profiling have demonstrated recurrent inactivation/losses/decreased expression of RB1 (retinoblastoma 1; 13q13-q21), LATS2 , CDKN1B , CDKN2A , and TP53 genes, 4 while next-generation sequencing (NGS) studies have demonstrated point mutations involving TET2 (~36%), ASXL1 (~32%), NRAS (~30%), ATM (21%), along with deletions involving RB1 and APC (~6%) 5 , 6 . In addition, recurrent MYB gene rearrangements have been documented in both children and adults, with fusion oncogenes including MYB-ZFAT , MYB-PLEKHO1 , and MYB-DCPS 7 . Common clonal origins for CMML and BPDCN have been suggested based on similar genetic and epigenetic deregulations identified, along with sporadic case reports of CMML transformation to BPDCN 8 , 9 . We provide the first in-depth whole-exome sequencing (WES) results on a patient with CMML that transformed to BPDCN and provide information with regards to possible mechanisms of transformation.
No takes yet. Share an insight, caveat, or question.
Patnaik et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: